StockData
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP) stock

TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.94+0.06 (+2.08%)

Close on Nov 17, 2026Market cap $50.42MP/E –Yield –

Tonix Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Tonix Pharmaceuticals's price to sales ratio was 2.2× on Nov 11, 2026, against 15.8× a year earlier. Over the last 3 years it ranged from 0.1× to 27.2×, with a median of 8.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.2×−13.2
2025Dec 31, 202515.4×+10.9
2024Dec 31, 20244.5×–

More Tonix Pharmaceuticals figures

See a number that looks wrong?